Citable filing context
HCA's research view summarizes recent SEC filing context, starting with debt_offering from Jul 29, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 29, 2026 | debt_offering | HCA increased its commercial paper program capacity from $4.0 billion to $8.0 billion. |
| Jul 24, 2026 | earnings | HCA Healthcare reported second quarter 2026 revenues of $20.23 billion and net income of $1.699 billion. |
| Jul 14, 2026 | guidance_update | HCA Healthcare updated its 2026 financial guidance, lowering revenue and net income expectations due to payer mix shifts. |
| Jul 24, 2026 | Guidance: adjusted_ebitda | 15400.00 to 16100.00 |
| Jul 24, 2026 | Guidance: eps_diluted | 28.70 to 30.50 |
| Jul 24, 2026 | Guidance: net_income | 6300.00 to 6700.00 |
| Jul 28, 2026 | mda_quarterly | HCA Healthcare reported second-quarter 2026 revenues of $20.23 billion, an 8.7% increase over the prior-year period, driven by a 6.0% rise in revenue per equivalent admission and a 2.6% increase in equivalent admissions. Net income attributable to HCA reached $1.699 billion, or $7.62 per diluted share. Performance was significantly bolstered by incremental revenues from the Florida Medicaid state directed payment program, which contributed to a 23.4% increase in same-facility uninsured admissions as the company navigated the expiration of enhanced premium tax credits (EPTCs) for insurance exchange plans. Operating expenses rose, with other operating expenses increasing to 24.9% of revenue, largely due to costs associated with Medicaid supplemental payment programs and professional fees. While inpatient and outpatient surgical volumes declined by 2.3% and 4.4% respectively, emergency department visits grew by 3.5%. The company maintains a robust capital structure, with $49.72 billion in total debt and $3.09 billion available under its senior unsecured credit facility. Management expects 2026 capital expenditures to range between $5.0 billion and $5.5 billion. Despite inflationary pressures and regulatory shifts in Medicaid funding, the company continues to prioritize share repurchases, having bought back 7.909 million shares during the first half of 2026. |
| Apr 29, 2026 | mda_quarterly | First-quarter 2026 revenues increased 4.3% to $19.109 billion, with net income attributable to HCA Healthcare, Inc. totaling $1.620 billion. Growth was primarily driven by a 3.1% increase in revenue per equivalent admission, which offset declines in outpatient surgical volumes (down 2.7%) and inpatient surgical volumes (down 0.4%). These volume pressures were attributed to a significant decrease in seasonal respiratory-related activity and a January winter storm. A critical trend is the 15.6% increase in consolidated uninsured admissions following the expiration of enhanced premium tax credits and administrative reforms, raising the estimated cost of total uncompensated care to $1.252 billion. Texas and Florida remain the most vital markets, generating 51% of revenues and 73% of uninsured admissions. Operating expenses were pressured by higher cardiovascular technology costs and increased state supplemental Medicaid program spending. Cash flow from operating activities rose to $2.014 billion, supporting $1.119 billion in capital expenditures and $1.571 billion in share repurchases. Total debt reached $48.023 billion. Primary financial risks include persistent inflationary pressures on labor and supplies, as well as regulatory uncertainty surrounding Medicaid state directed payment arrangements. |
Source: SEC EDGAR filing text and events; period Jul 29, 2026; filed Jul 29, 2026.
HCA company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.